PMID- 12010339
OWN - NLM
STAT- MEDLINE
DCOM- 20020711
LR  - 20190722
IS  - 0011-9059 (Print)
IS  - 0011-9059 (Linking)
VI  - 41
IP  - 3
DP  - 2002 Mar
TI  - Evaluation of dietary intake of vitamin E in the treatment of atopic dermatitis: 
      a study of the clinical course and evaluation of the immunoglobulin E serum 
      levels.
PG  - 146-50
AB  - BACKGROUND: Vitamin E (VE) is a potent antioxidant that can improve the immune 
      macrophage-mediated response, decrease the production and/or release of 
      prostaglandins in humans, and decrease the serum levels of immunoglobulin E (IgE) 
      in atopic subjects. AIM: To compare the effects of placebo (PL) and VE intake 
      (400 IU/day) on subjective symptoms and serum IgE levels in 96 subjects with 
      atopic dermatitis. MATERIALS AND METHODS: A single-blind clinical analysis was 
      performed on 96 subjects randomly divided into two groups. Fifty subjects were 
      given orally 400 IU (268 mg) of VE of natural origin, once a day for 8 months, 
      and 46 took PL for the same period. Complete blood count, serum IgE levels, 
      radioallergosorbent test (RAST) score, antinuclear antibodies (ANA), and 
      biochemical analysis were obtained at the time of enrollment and every 15 days 
      during the 8 months of the study. To evaluate VE therapy, a questionnaire was 
      sent to each subject for completion at the end of the study. RESULTS: The results 
      were as follows: (A) four subjects treated with VE worsened, compared to 36 in 
      the PL group; (B) six subjects in the VE group and five in the PL group showed no 
      change; (C) slight improvement was observed in 10 subjects in the VE group and 
      four in the PL group; (D) 23 of the 50 subjects treated with VE showed great 
      improvement, compared to only one in the PL group; and (E) there was almost 
      complete remission of atopic dermatitis in seven of the 50 subjects in the VE 
      group, but none in the PL group. Females showed less progression of atopic 
      dermatitis than males in both groups and a higher percentage of almost complete 
      remission (five females and two males). The range of serum IgE levels varied 
      markedly from 1005 to 490 IU/mL in the VE group and from 1239 to 812 IU/mL in the 
      PL group over 8 months. Subjects with great improvement and near remission of 
      atopic dermatitis in the VE group demonstrated a decrease of 62% in serum IgE 
      levels based on initial conditions, while, in subjects taking PL, the difference 
      was approximately 34.4%. No complications were observed in either group. A 
      remarkable improvement in facial erythema, lichenification, and the presence of 
      apparently normal skin was reported. Eczematous lesions healed mostly as a result 
      of decreased pruritus. CONCLUSIONS: The correlation between VE intake, IgE 
      levels, and the clinical manifestations of atopy indicates that VE could be an 
      excellent therapeutic tool for atopic dermatitis.
FAU - Tsoureli-Nikita, Evridiki
AU  - Tsoureli-Nikita E
AD  - Institute of Dermosciences, University of Siena, Siena, Italy. tlotti@unifi.it
FAU - Hercogova, Jana
AU  - Hercogova J
FAU - Lotti, Torello
AU  - Lotti T
FAU - Menchini, Giovanni
AU  - Menchini G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
RN  - 1406-18-4 (Vitamin E)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Dermatitis, Atopic/blood/*drug therapy/pathology
MH  - *Dietary Supplements
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/*blood
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Radioallergosorbent Test
MH  - Severity of Illness Index
MH  - Single-Blind Method
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Vitamin E/administration & dosage/*therapeutic use
EDAT- 2002/05/16 10:00
MHDA- 2002/07/12 10:01
CRDT- 2002/05/16 10:00
PHST- 2002/05/16 10:00 [pubmed]
PHST- 2002/07/12 10:01 [medline]
PHST- 2002/05/16 10:00 [entrez]
AID - 1423 [pii]
AID - 10.1046/j.1365-4362.2002.01423.x [doi]
PST - ppublish
SO  - Int J Dermatol. 2002 Mar;41(3):146-50. doi: 10.1046/j.1365-4362.2002.01423.x.